Celltrion secures FDA approval for bone disease biosimilars
Stoboclo is approved for treating postmenopausal osteoporosis in women, while Osenvelt is indicated for the prevention of skeletal-related complications in cancer patients with bone metastases and for giant cell tumors of bone. Both products have been approved for all indications covered by the original reference drugs in the US.
Prolia and Xgeva recorded approximately $6.59 billion combined in global sales in 2023, with the US market alone accounting for two-thirds of that at $4.39 billion.
Celltrion plans to launch Stoboclo and Osenvelt in the US market as early as this year, following the completion of a patent settlement agreement with the original drug developer.
In November, Celltrion became the first company in Korea to obtain approval for these biosimilars, ahead of competing products. It also secured approval from the European Commission last month, accelerating its efforts to expand sales in major global markets.
Celltrion has been making aggressive moves to broaden its treatment portfolio, gaining approval for biosimilars for autoimmune diseases, oncology, ophthalmology and bone disease across key global markets. So far this year, the company has obtained three product approvals in the US and four in Europe, totaling seven across both markets.
The company last year already surpassed its goal of establishing an 11-product portfolio in Korea by 2025. It recently met the same goal in Europe.
"Our recent approvals in major global markets reaffirm our in-house biosimilar development capabilities," a Celltrion official said. "We will focus on completing the remaining regulatory approvals for our pipeline products while ensuring the rapid market penetration of approved products to drive revenue growth."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Korea Herald
6 days ago
- Korea Herald
Celltrion's Q2 net falls 19.3% on provisions
Celltrion, a major South Korean biopharmaceutical company, said Wednesday its second-quarter net profit fell 19.3 percent from a year earlier due to provisions related to ongoing legal disputes. For the three months ended June 30, net profit declined to 63.3 billion won ($45.6 million) from 78.4 billion won in the same period last year, the company said in a regulatory filing. "We set aside provisions in preparation for potential compensation related to ongoing legal disputes. These provisions impacted our quarterly bottom line," a company spokesperson said, without elaborating. Operating profit more than tripled to 242.5 billion won from 72.4 billion won, while sales rose 9.9 percent to 961.5 billion won from 874.7 billion won. The company said increased global sales of its flagship biosimilars, including Remsima SC, Yuflyma and Vegzelma, supported quarterly earnings. These high-margin products accounted for 53 percent of total sales in the second quarter. In the first half of the year, net income surged 73 percent to 171.6 billion won from 99.2 billion won a year earlier. Celltrion expects strong earnings to continue in the second half, as it plans to gradually launch five new biosimilars -- Omlyclo, Avtozma, Eydenzelt, Stoboclo and Osenvelt -- in global markets later this year. The company aims to achieve 5 trillion won in annual sales this year, up 40 percent from a record 3.56 trillion won last year. Celltrion has significantly expanded its global biosimilar portfolio, with the number of approved products rising from six to 11. It plans to commercialize 22 biosimilar products by 2030, when the global market is projected to grow to 261 trillion won from 138 trillion won this year. (Yonhap)
Korea Herald
31-07-2025
- Korea Herald
Daewoong's Nabota hits record H1 sales, expands to Middle East
South Korean drugmaker Daewoong Pharmaceutical announced Thursday that its botulinum toxin product, Nabota, posted 115.4 billion won ($83 million) in revenue in the first half of this year, up 28 percent from last year. With this growth, Daewoong expects to surpass 200 billion won in annual sales this year. Nabota was approved by the US Food and Drug Administration in 2019 as the first Asian botulinum toxin. Since then, Daewoong has pursued a premium strategy focused on high purity, high safety and strict quality control standards. Nabota is now sold under the brand name Jeuveau in the US, the world's largest aesthetics toxin market, where it holds a 14 percent market share in the aesthetics segment, ranking second overall. Daewoong also continues to grow in Latin America and Southeast Asia, following major deals previously signed in Brazil and Thailand. The company recently signed a deal with Kuwait, expanding its reach to five Middle Eastern countries, including the UAE, Saudi Arabia and Qatar — the widest regional coverage among Korean toxin brands. Alongside product expansion, Daewoong is promoting its proprietary injection technique, Nabolift, through global training programs, aiming to enhance medical outcomes and brand presence. 'Nabota is now a global top-tier brand in aesthetics,' said Yoon Joon-soo, head of Daewoong Pharmaceutical's Nabota Business Division. 'We will strengthen our global leadership with premium quality and scientific proof.'
Korea Herald
29-07-2025
- Korea Herald
Celltrion nears US plant deal to go ‘made in USA'
Biosimilar giant to invest W700b in new US plant, double spending for expansion, chief says Celltrion Group Chairman and founder Seo Jung-jin said Tuesday that the company is preparing for new US tariffs by moving closer to acquiring a biologics manufacturing facility in the United States -- a move that would give Celltrion greater access to a market Seo framed as 'indispensable.' According to a regulatory filing Tuesday, Celltrion has been named the preferred bidder for a large-scale biologics manufacturing facility in the US, a cGMP or "current Good Manufacturing Practice" drug substance site located within a major pharmaceutical hub. The seller and deal value remain under wraps pending final agreement, expected in early October. 'The US is simply too big a market to walk away from, and we're aiming to eliminate uncertainty in our US sales,' said Seo during a livestreamed press conference Tuesday. 'If the US government wants drugs to be made in the US, then our plan is to produce them there accordingly.' Celltrion currently sells 11 biosimilars in the US, with plans to expand its portfolio to 22 by 2030 and 41 by 2033. It is also conducting Phase 1 trials for four novel drug candidates this year, with the goal of submitting investigational new drug applications for a total of 13 by 2028. Once due diligence is complete and the acquisition finalized, Celltrion is set to largely eliminate tariff-related risks for its pharmaceutical products in the US, backed by two years' worth of US-bound inventory and expanded contracts with local contract manufacturers. The deal includes a contract manufacturing agreement covering 50 percent of the facility's capacity, granting exclusive rights to produce the seller's biologics for five years. 'That means we won't be operating at a loss from day one,' Seo continued. 'The other half will be used to manufacture our own products for the US market.' He added that the potential acquisition brings a team of development personnel, which would complement Celltrion's existing research capabilities. Celltrion is also considering follow-up investments depending on how US tariff policies take shape. While the total cost of acquiring and operating the facility is expected to reach roughly 700 billion won ($503 million), Seo said a minor expansion could require an additional 300 billion won. 'In the case of a large-scale buildout, we estimate up to 700 billion won in extra investment,' he said. The expanded facility would be up to 1.5 times the size of Celltrion's second plant in Songdo, Incheon, he added. While highlighting the cost and time advantages of acquiring an existing facility, Seo noted that competition would likely remain limited due to high capital requirements and long lead times for local production. 'We believe US drug prices are likely to rise, and for companies that complete local production early, this could be a major opportunity,' he noted. As for the sales outlook, Seo said the company is on track to deliver 4.5 to 4.6 trillion won in sales this year -- of Celltrion's five trillion won full-year goal -- with operating profit expected to reach about 1.5 trillion won. In the second quarter, Celltrion posted record revenue and operating profit, with revenue rising 9.9 percent from a year earlier to 961.5 billion won and operating profit jumping 234.5 percent to 242.5 billion won.
